The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
The market has been reacting negatively to anything other than superb rns’s with a number of other companies. My worry is we could see a fall in the sp today.
“ eling a lot lot olderToday 10:25
There should be no reason for the so to dive.
We have a good amount of news due shortly (hopefully all good) and the only reason the price should drop is mm’s taking the p155...
Mm will give a shake to scare some holders as it’s a good way for mm to make money. Will it drop to 1p?
“ presume stop losses wont work tomorrow and its a case of riding out the short term pain?”
Could go 2 ways tomorrow. I expect it will open down and continue to fall. What I hope is for it to show an initial rise as mm try to fool the pi into thinking this isn’t going to fall, after that initial rise it will fall. Very difficult to get an auto price trade after the opening bell and likewise your trading platform will find it difficult to sell with any stop loss. But best of luck
Shame the company didn’t just release the stat sig pooled results and held the 2 subgroup’s results back. The SP dropped because the news was less than expected, same thing happened with SNG. Will the sp move south on the back of no news like SNG has done ?
Waking up rolling over then going back to sleep again.
It does that ever now and then to show it’s still alive. Upto 70 then slowly back down again.
Won’t see any sustained movement without news from NSCI or PDSB.
Not sure why pdsb sp has dropped on the back of this report?
Translation
The first vaccine against coronavirus developed entirely in Brazil has the potential to integrate global efforts in the search for definitive prevention against the effects of the pandemic.
This project is on an accelerated schedule and aims to carry out pre-clinical tests until October of this year and the beginning of clinical tests in the first quarter of 2021, with industrial production in the second half of 2021.
The vaccine that aims to prevent infection by Covid-19, developed by the Brazilian biotechnology company Farmacore, in partnership with PDS Biotechnology Corporation, has just received the support of the Financier of Studies and Projects (FINEP).
The prospect is that it will receive approval for funding by the National Council for Scientific and Technological Development (CNPq) to accelerate the development of the necessary tests to enable the vaccine before Anvisa.
“Vacina's production technology is easy to scale, which will enable its manufacture in Brazil and licensing to other countries,” explains Helena Faccioli, CEO of Farmacore.
The combination of Farmacore Biotecnologia and Versamune technologies from PDS Biotechnology is a new, extremely promising path to a double-acting and safe vaccine to fight coronavirus (COVID 19).
KNOW MORE
PDS Biotech is a clinical immunotherapy company with an increasing number of immunotherapies against cancer and vaccines against infectious diseases based on the Versamune® T-cell activation technology platform (intellectual property of the company).
Farmacore is a biotechnology company founded in 2005 as a startup, with a focus on research and development of innovative immunobiological products for use in the human and veterinary health sectors.
Versamune®-CoV-2FC is a vaccine project for COVID-19 that combines the Versamune® immune activation platform with a recombinant fusion protein developed by Farmacore from Coronavirus 2, from Severe Acute Respiratory Syndrome (SARS-CoV- 2). recognizable by our immune system (antigen).
LONDON (Reuters) - A new rapid test for COVID-19 has over 99% diagnostic sensitivity in early studies, scientists assessing the test at the University of Oxford said on Friday.
Public Health England official Steve Pullan said that early data indicated the LamPORE test was a credible alternative to conventional PCR-based diagnostics.
Nothing exciting in these results unfortunately. Recent sp movement just mm playing games?
Leaky was said last time it moves to mid 60’s only to slide down again.
I’ve put in an alert to tell me when this sp moves. These small fluctuations are normal aim variations. Nice to see it holding around 60 as it indicates the market hasn’t completely lost interest. Don’t expect to be disturbed for some time!
Yes it’s a great interview. Still early days so everything will depend on the versamune platform performing well in clinical trials and sufficient funding coming onboard. I would definitely put some money in for a longer term hold.
A peer review publication which supports the researchers report would give this product more street cred. With no news coming out I suspect, like lots of other AIM stocks, we can expect the SP to slowly drift down..